The Antibiotic You Gave May Not Have Been Necessary. This Study Is Building the Science to Prove It
Bovine respiratory disease drives more antibiotic use in beef cattle than any other condition. A new gene expression study just brought us significantly closer to knowing which animals actually needed treatment and which ones didn't.
Every food animal veterinarian knows the math on metaphylaxis.
High-risk cattle arrive. You do not know which ones are going to get sick. You do know that bovine respiratory disease is the most economically devastating illness in the beef cattle industry, responsible for the majority of feedlot morbidity and mortality and an enormous share of production losses across the entire sector. You know that by the time a calf is showing clinical signs, the disease is already ahead of you. And you know that waiting to find out who gets sick means some of those animals are going to get very sick very fast before you can intervene.
So you treat them all.
It is not a bad decision given the tools currently available. It is the decision the evidence supports, the decision the economics demand, and the decision most experienced feedlot veterinarians would make again tomorrow morning standing at the processing chute with a pen full of freshly commingled, recently transported, visibly stressed stocker cattle.
It is also, by definition, treating animals that did not need to be treated. And in an era of intensifying regulatory scrutiny on agricultural antibiotic use, mounting antimicrobial resistance concerns, and a profession increasingly asked to justify every gram of antimicrobial it puts into the food supply, that gap between who gets treated and who actually needed it is one of the most urgent problems in food animal medicine.
A study published this month in Scientific Reports just brought the profession meaningfully closer to closing it.
What the Study Found
Researchers from Texas A&M University, Mississippi State University, and West Texas A&M University performed whole-blood RNA sequencing on high-risk stocker cattle at arrival, then tracked BRD outcomes over the subsequent backgrounding period. The goal was to characterize the gene expression patterns present in these animals on the day they arrived — before any clinical signs appeared — and determine whether consistent immune and inflammatory pathways could be identified that distinguished animals that would go on to develop BRD from those that would not.
They found them.
Consistent, reproducible gene expression signatures linked to BRD outcomes were identified in the at-arrival transcriptome. Key pathways involved immune regulation, inflammatory response, and iron metabolism — including markers associated with innate immune function, viral recognition, and the kind of systemic inflammatory priming that sets the stage for respiratory disease to take hold when a pathogen arrives.
Among the most notable findings: genes including CD169/SIGLEC1, CD37, S100A8/A9, and IL-1R2 emerged as part of the expression landscape associated with BRD susceptibility. These are not arbitrary targets. CD169/SIGLEC1 has been studied as a biomarker of viral disease severity in other species. S100A8/A9 is a well-characterized marker of myeloid cell activation and systemic inflammation. The biological coherence of the pathways identified strengthens the case that what the researchers found is signal, not noise.
Why This Matters for Antimicrobial Stewardship
The antimicrobial stewardship implications of this research are direct and significant.
BRD is the leading driver of antibiotic use in beef cattle production in the United States. Metaphylaxis — the mass antimicrobial treatment of high-risk groups at arrival — is the standard of care precisely because the profession lacks reliable tools to identify which individual animals are genuinely at elevated risk versus which ones would have mounted an adequate immune response on their own. Without a way to tell them apart, treating the whole pen is the rational choice.
But the regulatory and scientific environment surrounding that choice is shifting. The FDA has been steadily tightening antimicrobial use guidelines in food animal production. Antimicrobial resistance is a global public health priority with agriculture in the crosshairs. And the industry is increasingly being asked to demonstrate not just that antimicrobials are used responsibly, but that they are used only where genuinely necessary.
If at-arrival gene expression profiling can reliably identify which animals are immunologically primed for BRD susceptibility, the clinical and stewardship implications cascade outward in every direction. Targeted metaphylaxis rather than blanket treatment. Objective risk stratification at processing. Reduced total antimicrobial volume without sacrificing animal health outcomes. And perhaps most importantly for the long-term trajectory of the profession: a scientifically defensible framework for making treatment decisions that goes beyond clinical judgment and pen-level risk assessment.
The At-Arrival Window
The timing embedded in this research is worth dwelling on. The gene expression signatures identified in this study were present on the day these animals arrived — before any clinical disease was detectable, before any diagnostic workup was possible, before any experienced clinician could have looked at these calves and told you which ones were going to end up as BRD cases.
The blood already knew.
That is not a metaphor. It is a literal description of what RNA sequencing of peripheral leukocytes reveals about the immunological state of an animal at the moment of arrival. The transcriptome is a snapshot of what every cell in that blood sample is currently doing — which genes are turned on, which are turned off, which inflammatory cascades are already in motion, and which immune pathways are primed or suppressed.
What this study demonstrates is that those snapshots contain meaningful, consistent, reproducible information about BRD risk. Not perfect prediction. Not a binary test that tells you with certainty which animal will get sick. But statistically coherent signal strong enough to form the foundation of a risk stratification tool that the profession does not currently have.
The Road From Research to Chute-Side
The honest caveat here is that whole-blood RNA sequencing is not yet a chute-side tool. It is a research technology. The pathway from transcriptomic signatures identified in a research setting to a validated, commercially available, field-deployable diagnostic is long, expensive, and uncertain in its timeline.
But that pathway is being walked. This study is one of a growing body of at-arrival transcriptomic research in BRD that is collectively building the scientific infrastructure for exactly that kind of tool. Each study that identifies consistent, biologically coherent gene expression patterns associated with BRD outcomes strengthens the case for investing in the translation work that turns laboratory findings into clinical reality.
The researchers were supported by the USDA National Institute of Food and Agriculture, Texas A&M AgriLife Research, the Texas A&M University College of Veterinary Medicine and Biomedical Sciences, and the Mikell and Mary Cheek Hall Davis Endowment for Beef Cattle Health and Reproduction at Mississippi State University. That breadth of institutional support reflects the seriousness with which the field is taking this research direction.
What Food Animal Practitioners Should Take Away
The conversation around antimicrobial stewardship in food animal medicine has too often been framed as a conflict between animal health and public health — as if treating sick cattle and protecting antibiotic efficacy for human medicine are inherently opposed goals that require compromise rather than innovation.
This study reframes that conversation. The goal is not to treat fewer animals. It is to treat the right animals — the ones whose immune systems are already telling you, in the language of gene expression, that they are going to need help. The ones for whom metaphylaxis is not a precaution but a necessity.
Science is building the tools to tell you which animals those are. They are not there yet. But they are getting closer, one transcriptome at a time.
The full study, "Gene expression links consistent immune and inflammatory pathways to bovine respiratory disease in high-risk stocker cattle," is published in Scientific Reports, 2026. Authors declared no competing interests.
